Navigation Links
New test for patients with sore throats cuts antibiotic use by nearly a third
Date:11/8/2013

, in which patients were told to pick up a prescription three to five days later if their symptoms did not settle or got worse.

Patients who had four or five of the clinical features of the FeverPAIN test were prescribed antibiotics immediately; a delayed antibiotic prescription was offered to patients with two or three features and no antibiotics to those with only one or no features.

The test led to a 29 per cent reduction in antibiotic use compared with the delayed prescription approach. One in three patients in the FeverPAIN score group said their sore throat had improved rapidly from a moderately bad problem to a slight problem within two to four days. Moderately bad or worse symptoms also got better faster in the clinical score group.

However, the use of a rapid antigen test as well as the FeverPAIN test for patients who displayed streptococci symptoms did not offer any further improvements, with a 27 per cent reduction in antibiotic use as well as similar improvements in patients' symptoms.

Study co-author Dr Michael Moore, a GP and a reader in primary care research at the University of Southampton, adds: "Clinicians can consider using a clinical score to target antibiotic use for acute sore throat, which is likely to reduce antibiotic use and improve symptom control. There is no clear advantage in the additional use of a rapid antigen test.

"We found that the FeverPAIN score picks up bacterial throat infections more accurately than the current scoring system and importantly picks up larger numbers of patients who are at low risk of streptococcal infection giving the patient and the doctor the confidence not to use antibiotics. If you select those at the highest risk of streptococcal infection then antibiotics can be more targeted at the people who are most likely to get symptom benefit."


'/>"/>

Contact: Becky Attwood
r.attwood@soton.ac.uk
0238-059-5457
University of Southampton
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Revisiting Prevention of Blood Clots in Chemotherapy Patients
2. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
3. Allegheny Health Network Partners with Region’s EMS Providers to Advance Treatment of Heart Attack Patients
4. AGA publishes tool to help GIs manage HCV patients
5. Transgender patients have special needs in the ER
6. Medical Factoring and Finance Company Alleon Capital Partners Closes a Financing Facility with Lab Serving Dialysis Patients
7. Patients Experience Impairments Just One Year After Knee Replacement Surgery, According to New Kantar Health Research
8. Pleasure and pain brain signals disrupted in fibromyalgia patients
9. Patients “Self-Refer” To Practices With Health Care Transparency Tools
10. Weighing in: 3 years post-op bariatric surgery patients see big benefits, Pitt study says
11. ScribeAmerica and Ochsner Health System Partner to Provide Efficient, Cost Conscious Healthcare for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 Supply & ... annual listing of “Pros to Know” in the supply ... two members of MEBC’s leadership team were included on ... nominated and received this award due to their hard ... innovative methods for meeting and resolving client needs and ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
(Date:3/5/2015)... March 05, 2015 Wimbledon Health ... provides vascular, echocardiogram and NCV testing, announced ... the Chief Medical Officer. Dr. Artel will be responsible ... of the WimbledonMED program and the continued growth and ... about working with Wimbledon Health Partners as a consulting ...
(Date:3/5/2015)... March 05, 2015 March 5, 2015 ... off next week (March 8-14, 2015), children’s hospitals around ... play in making hospital stays as safe as possible ... children’s hospitals—Children’s Hospitals’ Solutions for Patient Safety (SPS) and ... for families to follow when visiting the hospital with ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4
... at the chemical plan in the month of November released toxic ... in Russia also as they share the same water resources. // ... the danger of concentration of these chemicals due to the melting ... test to be carried out in a random fashion to make ...
... the moles which are seen among elderly Australians who run ... dangerous. // The country’s skin specialists believe that this is ... many as 309 patients were studied during the course of ... of the new moles on older patients being melanomas were ...
... a very low calories diet can help the heart age more ... to be the first ever human trial study. // ... demonstrate the cardiac benefits of a restricted calorie diet. ... the Caloric Restriction Society, ages 41 to 64, who consume 1,400 ...
... not feel threatened by the bird flu outbreaks in Turkey, ... reported to have already taken measures// to prevent the spread ... ready to face all possibilities of an outbreak. The Government ... virus. ,Money has already been apportioned by ...
... U.S. Army Medical Research Institute of Infectious Diseases have found ... protection and treatment of humans // from wild strains of ... has to be done as this Ebola virus offers a ... are published in the Journal Public Library of Science Pathogens. ...
... doctors it is imperative that global guidelines for giving iron ... The reason is// that since they might be dangerous ... by researchers from the United States and Tanzania. They called ... severe illness and death if they are given to children ...
Cached Medicine News:Health News:UN Fears Melting Of Ice Would Concentrate Toxins in the Chinese Water Supply 2
(Date:3/5/2015)... March 5, 2015  Relmada Therapeutics, Inc. (OTCQB: ... the treatment of chronic pain, today announced the ... advisory roles. The panel of experts will provide ... efforts to advance the company pipeline of novel ... expertise in a range of areas including opioid ...
(Date:3/5/2015)... 2015 LUNGevity Foundation, the nation,s leading ... Administration,s (FDA) approval of Bristol Myers Squibb,s new ... treatments add another critical new treatment option to ... a patient,s own immune system to fight cancerous ... for patients with squamous cell lung cancer, a ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Japan Pharma Outlook 2015: Year to Watch ... Initiatives" report to their offering. ... from April -2014 (Annexure 1) is a ... - whether generic or innovator. The most of the ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3
... 2011 Reportlinker.com announces that a new ... catalogue: Pharmaceutical Key Trends ... the pharmaceutical industry ... A number of factors have ...
... Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced ... Administration,s (the "FDA") Division of Oncology Drug Products (the ... New Drug Application (the "NDA") for pixantrone for relapsed ... for accelerated approval based on the PIX301 study results. ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry 2Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry 3Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry 4Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval 2Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval 3Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: